Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 405 clinical trials
None
  • 0 views
  • 07 Oct, 2021
  • 45 locations
None
A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer

TITLE:A Phase II non-comparative study of paclitaxel plus carboplatin in combination with Vorinostat in patients with advanced, recurrent epithelial ovarian cancer. INDICATION:Second-line treatment of patients with recurrent platinum-sensitive epithelial ovarian cancer. RATIONALE:Recurrent epithelial ovarian cancer is today an incurable disease. The current standard of care consists of systemic chemotherapy using …

recurrent ovarian cancer
paclitaxel
adenocarcinoma
carboplatin
topotecan
  • 10 views
  • 07 Nov, 2020
  • 1 location
None
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

Investigational agent, AZD6738 will be given in combination with Olaparib to women with recurrent ovarian cancer (platinum-sensitive or platinum-resistant). This study will determine if

  • 49 views
  • 07 Oct, 2021
  • 4 locations
None
Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer

This study aims to investigate the effect of involved-field radiotherapy for recurrent ovarian cancer after primary standard treatment. We will investigate whether the addition of involved-field

neutrophil count
ovarian carcinoma
carcinoma
  • 11 views
  • 22 Jan, 2021
  • 1 location
None
Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer

PARPi can play a synergistic anti-tumor role and achieve good efficacy in platinum-sensitive recurrent ovarian cancer. This study intends to explore the safety and effectiveness of anlotinib and

  • 0 views
  • 27 Jan, 2021
  • 1 location
None
  • 0 views
  • 28 Jan, 2021
  • 1 location
None
Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study

The aim of the study is to explore a prognostic clinical and molecular biomarker profile in a population of BRCA wild-type recurrent high-grade ovarian cancer patients treated with olaparib as maintenance after response to a platinum based therapy as platinum sensitive recurrence treatment.

  • 0 views
  • 13 Mar, 2021
  • 1 location
None
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor. Its primary targets are Hepatocyte growth factor receptor protein (MET), vascular endothelial growth factor receptor 1-3 (VEGFR1-3), RET, AXL, FLT3 and KIT. Cabozantinib has been approved by the FDA for clinical treatment of progressive, metastatic medullary thyroid cancer. Recently published trials have …

pd-l1
metastatic cancer
platinum-based chemotherapy
RET
oophorectomy
  • 46 views
  • 22 Sep, 2021
  • 12 locations
None
IGFBP-3 in Ovarian Cancer Invasion

An ovarian cancer cell line (OVTW-59) derived from an ovarian endometrioid carcinoma was established and its sublines, labeled as P0, P1, P2, P3, and P4 with increasing invasion abilities were selected from transwell invasion chambers.Using cDNA microarray and verified with quantitative reverse-transcriptase polymerase chain reaction, we have identified IGFBP-3 as …

endometrioid carcinoma
cancer
adenocarcinoma
ovarian cancer
carcinoma
  • 1 views
  • 07 Nov, 2020
  • 1 location
None
Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study

To determine the impact of Neoadjuvant chemotherapy on surgical debulking rate, overall and disease-free survival and quality of life (QOL) in patients with advanced EOC.

ovarian carcinoma
ovarian epithelial cancer
cancer
ovarian cancer stage
ovarian cancer
  • 19 views
  • 07 Nov, 2020
  • 1 location